Publicaciones científicas
Primary Prevention of Sudden Death in Patients With Valvular Cardiomyopathy
Moisés Rodríguez-Mañero 1 , María Teresa Barrio-López 2 , Emad Abu Assi 3 , Víctor Expósito-García 4 , Vicente Bertomeu-González 5 , Juan Miguel Sánchez-Gómez 6 , Luis González-Torres 7 , Ignacio García-Bolao 8 , Larraitz Gaztañaga 9 , Pilar Cabanas-Grandío 10 , José Antonio Iglesias-Bravo 11 , Álvaro Arce-León 12 , Ana Andrés la Huerta 13 , Juan Fernández-Armenta 14 , Rafael Peinado 15 , Miguel Angel Arias 16 , Ernesto Díaz-Infante 7
Introduction and objectives: Few data exist on the outcomes of valvular cardiomyopathy patients referred for defibrillator implantation for primary prevention. The aim of the present study was to describe the outcomes of this cardiomyopathy subgroup.
Methods: This multicenter retrospective study included consecutive patients referred for defibrillator implantation to 15 Spanish centers in 2010 and 2011, and to 3 centers after 1 January 2008.
Results: Of 1174 patients, 73 (6.2%) had valvular cardiomyopathy. These patients had worse functional class, wider QRS, and a history of atrial fibrillation vs patients with ischemic (n=659; 56.1%) or dilated (n=442; 37.6%) cardiomyopathy. During a follow-up of 38.1 ± 21.3 months, 197 patients (16.7%) died, without significant differences among the groups (19.2% in the valvular cardiomyopathy group, 15.8% in the ischemic cardiomyopathy group, and 17.9% in the dilated cardiomyopathy group; P=.2); 136 died of cardiovascular causes (11.6%), without significant differences among the groups (12.3%, 10.5%, and 13.1%, respectively; P=.1). Although there were no differences in the proportion of appropriate defibrillator interventions (13.7%, 17.9%, and 18.8%; P=.4), there was a difference in inappropriate interventions (8.2%, 7.1%, and 12.0%, respectively; P=.03).
Conclusions: All-cause and cardiovascular mortality in patients with valvular cardiomyopathy were similar to those in other patients referred for defibrillator implantation. They also had similar rates of appropriate interventions.
These data suggest that defibrillator implantation in this patient group confers a similar benefit to that obtained by patients with ischemic or dilated cardiomyopathy.
CITA DEL ARTÍCULO Rev Esp Cardiol (Engl Ed). 2016 Mar;69(3):272-8. doi: 10.1016/j.rec.2015.05.016. Epub 2015 Oct 23.
Nuestros autores
